Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etonogestrel + ethinyl estradiol is a combination hormonal contraceptive delivered via a flexible vaginal ring. It contains two active ingredients: etonogestrel (a progestin) and ethinyl estradiol (an estrogen). The ring is inserted into the vagina, where it continuously releases hormones over three weeks to prevent pregnancy. Its primary mechanism of action is suppression of ovulation by inhibiting gonadotropin secretion from the pituitary gland. Additional contraceptive effects include thickening cervical mucus to impede sperm penetration and altering the endometrial lining to reduce the likelihood of implantation. This combination is indicated for birth control in women of reproductive age and was first approved in 2001[1][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etonogestrel + ethinyl estradiol.